DBV Technologies
$ 13.05
0.46%
04 Dec - close price
- Market Cap 523,743,000 USD
- Current Price $ 13.05
- High / Low $ 13.42 / 12.96
- Stock P/E N/A
- Book Value 0.39
- EPS -5.20
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.77 %
- ROE -2.34 %
- 52 Week High 18.00
- 52 Week Low 2.74
About
DBV Technologies SA (DBVT) is a pioneering biopharmaceutical company headquartered in Montrouge, France, focused on revolutionizing food allergy treatment through its proprietary Viaskin™ technology platform. As a clinical-stage organization, DBV is dedicated to developing non-invasive epicutaneous immunotherapies aimed at promoting allergen desensitization, with a primary focus on peanut allergies. The company is currently advancing a robust pipeline through a series of clinical trials, positioning itself as a leader in addressing significant unmet medical needs in allergy management while striving to improve patient quality of life.
Analyst Target Price
$20.65
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-28 | 2025-07-29 | 2025-04-11 | 2025-03-05 | 2024-11-07 | 2024-07-30 | 2024-05-09 | 2024-03-07 | 2023-10-31 | 2023-07-31 | 2023-05-04 | 2023-03-02 |
| Reported EPS | -0.24 | -0.31 | -0.23 | -0.2126 | -1.4909 | -0.34 | -0.56 | -0.0581 | -0.08 | -0.12 | -0.22 | -0.44 |
| Estimated EPS | -0.2917 | -0.1567 | -0.2267 | -0.21 | -1.6425 | -0.45 | -0.21 | -0.23 | -0.22 | -0.19 | -0.2067 | -0.17 |
| Surprise | 0.0517 | -0.1533 | -0.0033 | -0.0026 | 0.1516 | 0.11 | -0.35 | 0.1719 | 0.14 | 0.07 | -0.0133 | -0.27 |
| Surprise Percentage | 17.7237% | -97.8302% | -1.4557% | -1.2381% | 9.2298% | 24.4444% | -166.6667% | 74.7391% | 63.6364% | 36.8421% | -6.4344% | -158.8235% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DBVT
2025-10-17 13:16:00
DBV Technologies (DBVT) saw its shares jump 6.8% due to increased investor optimism regarding its proprietary Viaskin technology for food allergies. While the company is expected to report a quarterly loss, future revenue growth is anticipated, though earnings estimate revisions have remained flat. Investors are advised to monitor future developments to see if this momentum continues.
2025-09-03 16:30:00
DBV Technologies (NASDAQ:DBVT), a clinical-stage biopharmaceutical company, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. CEO Daniel Tassé will deliver a fireside chat on September 9, 2025, at 11:30 AM ET in New York. The presentation will be available via live webcast and for replay on the company's investor relations website for 90 days.
2024-12-05 00:00:00
DBV Technologies is optimistic about the Food and Drug Administration approval of its Viaskin patch for peanut allergy, with an accelerated approval designation for toddlers. The company is also making progress on studies for milk allergy and plans for other allergens like cashew. Viaskin patch offers a potential alternative to existing treatments especially for younger children, with further studies ongoing and results expected by the end of 2025.
2024-10-22 16:45:00
DBV Technologies announced positive regulatory updates for its Viaskin Peanut patch in the United States and Europe. The company received guidance from the FDA for an Accelerated Approval pathway for toddlers aged 1-3 years old and positive scientific advice from the EMA for a 1-7 year-old indication. This news highlights significant progress in bringing the treatment to young patients with peanut allergy, with a BLA submission expected to follow a supplemental safety study.
2024-09-28 00:00:00
This article reviews epicutaneous immunotherapy (EPIT) as a novel treatment for peanut allergy, focusing on Viaskin™ Peanut. It details the mechanism of action, which involves the skin's immune system to promote tolerance, and synthesizes findings from extensive preclinical research and multiple phase 2 and 3 human clinical trials. The studies demonstrate Viaskin Peanut's efficacy, particularly in younger children, and its favorable safety profile with mostly mild-to-moderate skin reactions, suggesting it as a practical and well-tolerated therapeutic option.
2024-09-23 20:30:00
DBV Technologies has announced the completion of patient screening for its VITESSE Phase 3 clinical trial, which evaluates the Viaskin® Peanut Patch in peanut-allergic children aged 4-7 years old. The company exceeded its recruitment goal and expects topline results by Q4 2025. This 12-month study, the largest immunotherapy clinical trial for this patient population, has enrolled over 600 subjects across 86 sites globally.
